TMCnet News

Pancreatic Cancer 2015-2024: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis - Research and Markets

[August 11, 2016]

Pancreatic Cancer 2015-2024: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis - Research and Markets

Research and Markets has announced the addition of the "Pancreatic Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

The prognosis of patients with pancreatic cancer remains poor; however, this clinical need will drive future market expansion and the development of several targeted therapies.

This report addresses the following questions:

- What are the current treatment options for patients with pancreatic cancer in each therapeutic setting?

- Which products will drive growth of the pancreatic cancer market during 2015-24?

- Which brands will experience generic competition over the course of the forecast period and what impact will this have on the value of the overall pancreatic cancer market?

- How do pipeline therapies compare in terms of their clinical and commercial attractiveness, and how are companies attempting to differentiate their products?

- Which pipeline products will have a limited uptake in the pancreatic cancer market?

Key Topics Covered:

FORECAST: PANCREATIC CANCER

- Executive Summary

- Market Overview and Trends

- Market Definition and Methodology

- Abraxane (albumin-bound paclitaxel)

- Momelotinib

- Tarceva (erlotinib)

- Primary Research Methodology

TREATMENT: PANCREATIC CANCER

- Executive Summary

- Survey Methodology

- Disease Definition and Diagnosis

- Patient Segmentation

- Country Treatment Trees

- Current Treatment Options

- Prescribing Trends

EPIDEMIOLOGY: PANCREATIC CANCER

- Executive Summary

- Sources and Methodology

- Forecast

- Epidemiologist Insight,

- Strengths and Limitations

MARKETED DRUGS: PANCREATIC CANCER

- Executive Summary

- Product Overview

- Product profile: Abraxane

- Product profile: Onivyde

- Product profile: TS-

- Product profile: Tarceva

PIPELINE: PANCREATIC CANCER

- Executive Summary

- Clinical Pipeline Overview

- Product profile (late stage): HyperAcute-Pancreas

- Product profile (late stage): Lynparza

- Product profile (late stage): Polyclonal Antibody Stimulator

- Product profile (late stage): Yttrium-

- clivatuzumab tetraxetan

- Product profile (late stage): masitinib

- Product profile (late stage): momelotinib

For more information about this report visit http://www.researchandmarkets.com/research/rsstt5/pancreatic